Overview
Meropenem vs Cefotaxime as Empirical Treatment of SBP
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-02-01
2024-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Assiut UniversityTreatments:
Cefotaxime
Cefoxitin
Meropenem
Criteria
Inclusion Criteria:- Liver cirrhosis patients with ascites Ascitic fluid PMN cell count >250/mm3 Age: 18:80
Exclusion Criteria:
- : history of abdominal surgery within 4 weeks, secondary peritonitis, tuberculous
peritonitis, Malignant tumor, patients who use hormones or immunosuppressants, AIDS
patients.